On November 8, 2026, myeloproliferative neoplasm (MPN) societies celebrated the expanding real-world registry success of Ojjaara® (Momelotinib 100 mg, 150 mg, and 200 mg film-coated tablets) by GSK for myelofibrosis patients with moderate-to-severe anemia.

While first-generation JAK1/2 inhibitors like ruxolitinib improve splenomegaly and systemic constitutional symptoms, they systematically worsen anemia and frequently necessitate RBC transfusions. Momelotinib uniquely combines JAK1/JAK2 inhibition with potent ACVR1 (activin A receptor type 1 / ALK2) inhibition, concurrently shrinking spleen volume and resolving anemia.

Through Critical Kare Pharma, certified genuine packs of Ojjaara Momelotinib Tablets are supplied directly to practicing hematologists and hospital pharmacies internationally.

ACVR1 Inhibition & Hepcidin Downregulation

In myelofibrosis, excessive bone marrow inflammation triggers hepatic hyperproduction of hepcidin via bone morphogenetic protein (BMP)/ACVR1 signaling. Circulating hepcidin degrades ferroportin, trapping iron in macrophages and hepatocytes and starving erythropoiesis. Momelotinib blocks ACVR1, sharply reducing serum hepcidin, restoring systemic iron mobilization, and boosting functional hemoglobin synthesis.

Pivotal Phase 3 MOMENTUM Trial Benchmarks

• Total Symptom Score (TSS) Reduction: 25% of momelotinib-treated anemic, symptomatic patients achieved ≥ 50% TSS reduction at Week 24 versus 9% on danazol.
• Transfusion Independence (TI): Over 30% of previously transfusion-dependent patients achieved complete transfusion independence sustained for ≥ 12 weeks.
• Spleen Volume Reduction (SVR35): 23% achieved ≥ 35% reduction in spleen volume, validating sustained dual JAK/ACVR1 efficacy.

Clinical Dosing & Supply Protocols

Standard dosing is 200 mg orally once daily with or without food. Critical Kare Pharma manages international import permits, temperature-protected shipment, and named-patient documentation for tertiary medical centers worldwide.